What Is Catalyst Pharmaceuticals, Inc. (CPRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Catalyst Pharmaceuticals, Inc. presents a highly debated valuation profile at its current price of $31.48. The composite intrinsic value is estimated at $29.93 (-4.9% average upside), masking a wide model spread between the 5 bullish models and 6 bearish models. Model dispersion is worth noting: ML-RIV targets $48.75 (+54.9%), versus Dynamic NAV at $5.74 (-81.8%). This +136.6% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Markov DDM lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About CPRX?
13 of 13 models are currently active for CPRX. Of these, 6 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates CPRX's intrinsic value at $41.72, implying +32.5% upside from the current price. See which stocks rank higher →
How Does CPRX Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, CPRX ranks #2 by Quality of Company score. CirclFi's QOC score of 10.0/10 evaluates 32 fundamental signals. A score of 10.0 places CPRX in the top tier.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Catalyst Pharmaceuticals, Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating CPRX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is CPRX a Value Trap?
CirclFi's Value Trap algorithm assigns CPRX a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Catalyst Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Catalyst Pharmaceuticals, Inc.'s fundamental quality profile registers 10.0/10. This exceptional score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +136.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CPRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CPRX's 13 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad